Fig. 2

Survival analysis based on pre-therapy levels of serum IL-6 and CRP in NSCLC patients treated with PD-1/PD-L1 inhibitors. Overall survival (OS) according to baseline serum IL-6 levels (high vs. low) in NSCLC patients treated with anti-PD-1/anti-PD-L1 (A-C). OS in all patients (A), in patients with no/low PD-L1 tumor expression (B), and in patients with high PD-L1 tumor expression (C). Survival outcomes in patients with NSCLC without durable clinical benefit following anti-PD-(L)1, according to baseline CRP levels (D-F). OS from the start of immune checkpoint inhibitors (D), OS from time of progression with immune checkpoint inhibitors (E), and PFS from the start of immune checkpoint inhibitors (F). A-C modified from Kang, ref. [27]; copyright © 2020. The Korean Association of Immunologists. D-F modified from Harutani, ref. [38]; copyright © 2022, Springer Nature